Garly ML - Search Results

1

Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy.

Garly ML, Martins CL, Balé C, da Costa F, Dias F, Whittle H, Aaby P. Garly ML, et al. Int J Epidemiol. 1999 Apr;28(2):347-52. doi: 10.1093/ije/28.2.347. Int J Epidemiol. 1999. PMID: 10342702 Clinical Trial.

2

A comparison of ex vivo cytokine production in venous and capillary blood.

Eriksson M, Sartono E, Martins CL, Balé C, Garly ML, Whittle H, Aaby P, Pedersen BK, Yazdanbakhsh M, Erikstrup C, Benn CS. Eriksson M, et al. Among authors: garly ml. Clin Exp Immunol. 2007 Dec;150(3):469-76. doi: 10.1111/j.1365-2249.2007.03515.x. Epub 2007 Oct 9. Clin Exp Immunol. 2007. PMID: 17924971 Free PMC article. Clinical Trial.

3

Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines.

Roth AE, Stensballe LG, Garly ML, Aaby P. Roth AE, et al. Among authors: garly ml. Tuberculosis (Edinb). 2006 Nov;86(6):397-403. doi: 10.1016/j.tube.2006.02.001. Epub 2006 Aug 8. Tuberculosis (Edinb). 2006. PMID: 16901755 Review.

4

Bacillus Calmette-Guérin vaccination and infant mortality.

Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. Roth A, et al. Among authors: garly ml. Expert Rev Vaccines. 2006 Apr;5(2):277-93. doi: 10.1586/14760584.5.2.277. Expert Rev Vaccines. 2006. PMID: 16608427 Review.

5

BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens.

Garly ML, Balé C, Martins CL, Baldé MA, Hedegaard KL, Whittle HC, Aaby P. Garly ML, et al. Vaccine. 2001 Nov 12;20(3-4):468-74. doi: 10.1016/s0264-410x(01)00339-5. Vaccine. 2001. PMID: 11672911 Clinical Trial.

6

Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine.

Garly ML, Balé C, Martins CL, Monteiro M, George E, Kidd M, Dias F, Aaby P, Whittle HC. Garly ML, et al. Vaccine. 2001 Feb 28;19(15-16):1951-9. doi: 10.1016/s0264-410x(00)00431-x. Vaccine. 2001. PMID: 11228365 Clinical Trial.

7

Toxoplasmosis in Danish AIDS patients.

Garly ML, Petersen E, Pedersen C, Lundgren JD, Gerstoft J. Garly ML, et al. Scand J Infect Dis. 1997;29(6):597-600. doi: 10.3109/00365549709035902. Scand J Infect Dis. 1997. PMID: 9571741

8

Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A₂.

Ivaškevičius V, Biswas A, Garly ML, Oldenburg J. Ivaškevičius V, et al. Among authors: garly ml. Haemophilia. 2017 May;23(3):e194-e203. doi: 10.1111/hae.13233. Haemophilia. 2017. PMID: 28520207

9

Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.

Kerlin BA, Inbal A, Will A, Williams M, Garly ML, Jacobsen L, Kearney SL. Kerlin BA, et al. Among authors: garly ml. J Thromb Haemost. 2017 Aug;15(8):1601-1606. doi: 10.1111/jth.13748. Epub 2017 Jul 10. J Thromb Haemost. 2017. PMID: 28581691 Free article. Clinical Trial.

10

Safety and effectiveness of recombinant factor XIII-A₂ in congenital factor XIII deficiency: Real-world evidence.

Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Poulsen LH, et al. Among authors: garly ml. Res Pract Thromb Haemost. 2022 Feb 27;6(2):e12628. doi: 10.1002/rth2.12628. eCollection 2022 Feb. Res Pract Thromb Haemost. 2022. PMID: 35243202 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results